REVB Q1 2022 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$21,222

Operating Income

-$7M

Net Income

-$7M

EPS (Diluted)

$-7826.95

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$137,892

Balance Sheet

Total Assets

$8M

Total Liabilities

$8M

Stockholders' Equity

-$98,511

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$21,222	-$9,972	-112.8%
Operating Income	-$7M	-$3M	-152.6%
Net Income	-$7M	-$3M	-153.3%